PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsOritavancin
Orbactiv, Tenkasi (previously orbactiv)(oritavancin)
Kimyrsa, Orbactiv, Tenkasi (oritavancin) is an unknown pharmaceutical. Oritavancin was first approved as Orbactiv on 2014-08-06. It is used to treat bacterial infections, infectious skin diseases, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial skin diseases and soft tissue infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Kimyrsa, Orbactiv
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oritavancin diphosphate
Tradename
Company
Number
Date
Products
KIMYRSAMelinta TherapeuticsN-214155 RX2021-03-12
1 products, RLD, RS
ORBACTIVMelinta TherapeuticsN-206334 RX2014-08-06
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
kimyrsaNew Drug Application2021-07-30
orbactivNew Drug Application2022-02-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
infectious skin diseases—D012874—
streptococcal infectionsEFO_1001476D013290—
staphylococcal infections—D013203A49.01
Agency Specific
FDA
EMA
Expiration
Code
ORITAVANCIN DIPHOSPHATE, KIMYRSA, MELINTA THERAP
2024-08-06GAIN
2024-03-12NP
2019-08-06NCE
ORITAVANCIN DIPHOSPHATE, ORBACTIV, MELINTA THERAP
2024-08-06GAIN
2019-08-06NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Oritavancin Diphosphate, Kimyrsa, Melinta Therap
96493522035-07-16DP
96820612030-04-26U-1569, U-3101
84205922029-08-29U-1570, U-3101
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XA: Glycopeptide antibacterials
— J01XA05: Oritavancin
HCPCS
Code
Description
J2406
Injection, oritavancin (kimyrsa), 10 mg
J2407
Injection, oritavancin (orbactiv), 10 mg
Clinical
Clinical Trials
19 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—122319
Communicable diseasesD003141——112318
Bacterial skin diseasesD017192——11—2—4
BacteremiaD016470EFO_0003033R78.81———2—2
Soft tissue infectionsD018461—————2—2
Staphylococcal infectionsD013203—A49.01———1—1
EndocarditisD004696HP_0100584————1—1
Skin diseasesD012871—L00-L99———1—1
Opioid-related disordersD009293EFO_0005611F11———1—1
Substance-related disordersD019966EFO_0003890F13———1—1
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AbscessD000038EFO_0003030——12——3
CellulitisD002481EFO_0003035L03.90—12——3
InflammationD007249MP_0001845———2——2
Wound infectionD014946————2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Wounds and injuriesD014947—T14.8—1———1
Staphylococcal skin infectionsD013207EFO_1001849L00—1———1
Infectious skin diseasesD012874———1———1
Streptococcal infectionsD013290EFO_1001476——1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———6————6
Bacterial infectionsD001424—A491———12
Gram-positive bacterial infectionsD016908——1———12
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic footD017719EFO_1001459—————11
Foot ulcerD016523——————11
OsteitisD010000——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOritavancin
INNoritavancin
Description
Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.
Classification
Small molecule
Drug classvancomycin-related compounds
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O[C@H]3C[C@](C)(N)[C@@H](O)[C@H](C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(NCc3ccc(-c4ccc(Cl)cc4)cc3)[C@@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Identifiers
PDB—
CAS-ID171099-57-3
RxCUI—
ChEMBL IDCHEMBL1688530
ChEBI ID82699
PubChem CID16131319
DrugBankDB04911
UNII IDPUG62FRZ2E (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Orbactiv – The Medicines Company
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Orbactiv – Melinta Therapeutics /new/
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,573 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,045 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use